These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24703530)

  • 41. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
    Woo J; Palmisiano N; Tester W; Leighton JC
    Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
    Chu E
    Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
    [No Abstract]   [Full Text] [Related]  

  • 43. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant therapy after hepatectomy for colorectal metastases.
    Fong Y
    Lancet Oncol; 2014 May; 15(6):544-5. PubMed ID: 24807857
    [No Abstract]   [Full Text] [Related]  

  • 45. Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Berretta M; Martellotta F; Simonelli C; Di Benedetto F; De Ruvo N; Drigo A; Bearz A; Spina M; Zanet E; Berretta S; Tirelli U
    J Chemother; 2007 Jun; 19(3):343-6. PubMed ID: 17594933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastrointestinal cancer: FOLFOXIRI-improving outcomes of metastatic colorectal cancer.
    Errico A
    Nat Rev Clin Oncol; 2014 Dec; 11(12):684. PubMed ID: 25384949
    [No Abstract]   [Full Text] [Related]  

  • 49. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.
    Licitra L; Störkel S; Kerr KM; Van Cutsem E; Pirker R; Hirsch FR; Vermorken JB; von Heydebreck A; Esser R; Celik I; Ciardiello F
    Eur J Cancer; 2013 Apr; 49(6):1161-8. PubMed ID: 23265711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].
    Shimodaira H
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():582-6. PubMed ID: 25831827
    [No Abstract]   [Full Text] [Related]  

  • 52. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New combinations in metastatic colorectal cancer: what are our expectations?
    Hurwitz H
    Oncologist; 2005 May; 10(5):320-2. PubMed ID: 15851788
    [No Abstract]   [Full Text] [Related]  

  • 54. Two new drugs for colon cancer.
    Med Lett Drugs Ther; 2004 Jun; 46(1184):46-8. PubMed ID: 15184808
    [No Abstract]   [Full Text] [Related]  

  • 55. Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
    Hurwitz HI; Lyman GH
    J Clin Oncol; 2012 Feb; 30(6):580-1. PubMed ID: 22253468
    [No Abstract]   [Full Text] [Related]  

  • 56. Response phenotype as a predictive biomarker to guide treatment with targeted therapies.
    Oxnard GR; Schwartz LH
    J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750
    [No Abstract]   [Full Text] [Related]  

  • 57. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T
    Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010
    [No Abstract]   [Full Text] [Related]  

  • 58. EGFR antibodies in colorectal cancer: where do they belong?
    Grothey A
    J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
    [No Abstract]   [Full Text] [Related]  

  • 59. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.
    Chen MC; Chiang FF; Wang HM
    Neoplasma; 2013; 60(5):561-7. PubMed ID: 23790176
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
    Lieu CH; Messersmith WA
    JAMA; 2017 Jun; 317(23):2376-2378. PubMed ID: 28632850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.